This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer’s disease study ± 2 (DIADS-2)?


Drye, Lea T., Martin, Barbara K., Frangakis, Constantine E., Meinert, Curtis L., Mintzer, Jacobo E., Munro, Cynthia A., Porsteinsson, Anton P., Rabins, Peter V., Rosenberg, Paul B., Schneider, Lon S., Weintraub, Daniel, Lyketsos, Constantine G.


International Journal Of Geriatric Psychiatry, Volume: 26, No.: 6, Pages.: 573-583

Year of Publication



Objective: To determine if the effect of sertraline in the depression in Alzheimer’s disease study – 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria.; Methods: DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression in patients with Alzheimer’s disease. DIADS-2 enrolled 131 patients who met criteria for the depression of Alzheimer’s disease (dAD). Analyses reported here examined if the effect of sertraline differed in various subgroups, including those meeting criteria for major depressive episode (MaD), minor depressive episode (MiD), and Alzheimer’s-associated affective disorder (AAAD) at baseline.; Results: At baseline, 52 of 131 participants (39.7%) met criteria for MaD, 54 (41.2%) for MiD, and 90 (68.7%) for AAAD. For the primary outcome of modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) scores at 12 weeks of follow-up, the odds of being at or better than a given mADCS-CGIC category did not significantly differ between the two treatment groups for those patients with MaD at baseline (OR(sertraline)  = 0.66 [95% CI: 0.24, 1.82], p = 0.42); tests for interactions between treatment group and baseline depression diagnostic subgroup were not significant for MaD versus MiD versus neither (χ(2)  = 1.05 (2df), p = 0.59) or AAAD versus no AAAD (χ(2)  = 0.06 (1df), p = 0.81).; Conclusions: There was no evidence that sertraline treatment was more efficacious in those patients meeting baseline criteria for MaD compared to MiD or to neither.; Copyright © 2010 John Wiley & Sons, Ltd.

Bibtex Citation

@article{Drye_2011, doi = {10.1002/gps.2565}, url = {}, year = 2011, month = {apr}, publisher = {Wiley-Blackwell}, volume = {26}, number = {6}, pages = {573--583}, author = {Lea T. Drye and Barbara K. Martin and Constantine E. Frangakis and Curtis L. Meinert and Jacobo E. Mintzer and Cynthia A. Munro and Anton P. Porsteinsson and Peter V. Rabins and Paul B. Rosenberg and Lon S. Schneider and Daniel Weintraub and Constantine G. Lyketsos}, title = {Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer{textquotesingle}s disease study $pm$ 2 ({DIADS}-2)?}, journal = {Int. J. Geriat. Psychiatry} }


aged, aged, 80 and over, alzheimer disease, antidepressive agents, depressive disorder, diagnosis, drug therapy, female, humans, male, outcome assessment (health care), psychiatric status rating scales, psychology, serotonin uptake inhibitors, sertraline, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Depression and Anxiety

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants